Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Protara Therapeutics ( (TARA) ) is now available.
On December 4, 2025, Protara Therapeutics entered into an Underwriting Agreement with several underwriters to sell 13,043,479 shares of common stock at $5.75 per share, closing the offering on December 8, 2025. The company expects to raise approximately $75 million in gross proceeds, which will be used to fund the clinical development of TARA-002 and other programs, as well as for general corporate purposes.
The most recent analyst rating on (TARA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.
Spark’s Take on TARA Stock
According to Spark, TipRanks’ AI Analyst, TARA is a Underperform.
Protara Therapeutics faces considerable challenges typical in early-stage biotech, such as no revenue and persistent cash outflows. However, the strong equity and low debt levels provide some stability. The recent positive trial results are promising, but the stock remains high-risk due to its financial and operational metrics.
To see Spark’s full report on TARA stock, click here.
More about Protara Therapeutics
Protara Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of treatments for rare and specialty diseases. The company is primarily engaged in advancing clinical programs, including TARA-002, a key therapeutic candidate.
Average Trading Volume: 728,718
Technical Sentiment Signal: Buy
Current Market Cap: $215.3M
For a thorough assessment of TARA stock, go to TipRanks’ Stock Analysis page.